文献速递白血病造血干细胞移植与细胞治疗

核心结合因子AML患者第二次完全缓解期单倍体相合与同胞相合或无关供者造血细胞移植比较:单倍体相合移植复发率更低——来自全球委员会与欧洲血液和骨髓移植学会急性白血病工作组的报告

Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
PubMed 文献 · Am J Hematol · 2024-04-24

该研究基于EBMT全球多中心注册数据,比较了2010至2022年间227个中心865例第二次完全缓解期核心结合因子AML患者接受单倍体相合、同胞相合或10/10相合无关供者移植的结局。多因素分析显示单倍体相合移植复发率低于同胞相合(HR=0.56,95%CI 0.32-0.97)和无关供者(HR=0.57,95%CI 0.33-0.99),三种供者类型间无白血病生存、总生存和移植物抗宿主病无复发生存无显著差异;t(8;21)较inv(16)复发率和非复发死亡率更高。

要点

  • 第二次完全缓解期核心结合因子AML患者中,单倍体相合移植较同胞相合或无关供者移植复发率更低。
  • 三种供者类型间无白血病生存、总生存和移植物抗宿主病无复发生存无显著差异。
  • t(8;21)较inv(16)患者移植后复发率和非复发死亡率更高,无白血病生存、总生存和移植物抗宿主病无复发生存更差。

核心结论

  • 对于第二次完全缓解期核心结合因子AML患者,单倍体相合移植较同胞相合和无关供者移植与更低的复发率相关,无白血病生存、总生存和移植物抗宿主病无复发生存无差异。
  • 第二次完全缓解期接受移植的核心结合因子AML患者中,inv(16)较t(8;21)预后更好。

研究设计与样本

  • 该研究为EBMT全球多中心注册数据库分析,纳入2010至2022年在227个EBMT中心接受异基因造血细胞移植的865例新诊断成人核心结合因子AML第二次完全缓解期患者。
  • 纳入患者中同胞相合供者329例、10/10相合无关供者374例、单倍体相合供者162例。

主要发现

  • 全队列中503例(58%)为inv(16)/CBFB-MYH11 AML,362例(42%)为t(8;21)/RUNX1-RUNX1T1 AML。
  • 多因素分析中,单倍体相合移植较同胞相合供者移植复发率更低(HR=0.56,95%CI 0.32-0.97;p<.05),较无关供者移植复发率亦更低(HR=0.57,95%CI 0.33-0.99;p<.05)。
  • 三种供者类型之间无白血病生存、总生存和移植物抗宿主病无复发生存无显著差异。
  • t(8;21)较inv(16)患者复发率更高(HR=1.79,95%CI 1.3-2.47;p<.01),非复发死亡率亦更高(HR=1.58,95%CI 1.1-2.27;p<.01),导致无白血病生存、总生存和移植物抗宿主病无复发生存更差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended for core-binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor preference remains unclear. We compared in this EBMT global multicenter registry-based analysis the allo-HCT outcomes using either haploidentical (Haplo), matched siblings donors (MSD), or 10/10 matched unrelated donors (MUD). Data from 865 de novo adult CBF AML patients in CR2 receiving allo-HCT in 227 EBMT centers from 2010 to 2022 were analyzed, in which 329 MSD, 374 MUD, and 162 Haplo-HCTs were included. For the entire cohort, 503 (58%) patients were inv(16)/CBFB-MYH11 and 362 patients (42%) were t(8;21)/RUNX1-RUNX1T1 AML. On multivariate analysis, Haplo-HCT was associated with a lower Relapse Incidence (RI) compared to either MSD (hazard ratio [HR] = 0.56, 95% CI 0.32-0.97; p < .05) or MUD (HR = 0.57, 95% CI: 0.33-0.99, p < .05). No significant difference was observed among the 3 types of donors on LFS, OS and GRFS. CBF-AML with t(8;21) was associated with both higher RI (HR = 1.79, 95% CI 1.3-2.47; p < .01) and higher NRM (HR = 1.58, 95% CI 1.1-2.27; p < .01) than CBF-AML with inv(16), which led to worse LFS, OS and GRFS. To conclude, for CBF-AML patients in CR2, Haplo-HCTs were associated with a lower RI compared to MSD and MUD allo-HCTs. There was no difference on LFS, OS or GRFS. CBF AML patients with inv(16) had a better progonosis than those with t(8;21) after allo-HCT in CR2.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ye Y, Labopin M, Gérard S, et al. Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2024. PMID: 38654658. doi:10.1002/ajh.27342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。